All In Biotech

Drug Trial Radar · NCT03431350

A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

136

Actual

Start

Mar 2, 2018

Primary completion

Aug 31, 2021

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Feb 13, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to: a) establish the recommended phase 2 dose (RP2D) and to evaluate the antitumor activity and safety of niraparib combination therapies (Combinations 1 and 2) and b) to determine the relative bioavailability of niraparib and abiraterone acetate (AA) in combination (Combination 3) in participants with metastatic castration-resistant prostate cancer (mCRPC).

Conditions

  • Prostatic Neoplasms, Castration-Resistant

Interventions

  • Niraparib 200 mgDrug

    Participants will receive niraparib 200 mg orally.

  • Cetrelimab 240 mgDrug

    Participants will receive cetrelimab 240 mg IV every 2 weeks.

  • Cetrelimab 480 mgDrug

    Participants will receive cetrelimab 480 mg IV every 4 weeks.

  • Abiraterone acetate 1000 mgDrug

    Participants will receive AA 1000 mg orally.

  • Prednisone 5 mgDrug

    Participants will receive prednisone 5 mg orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Combination 1: Part 1: Number of Participants With Specified ToxicityTime frame: Cycle 1 (28 days)
  2. Combination 1: Part 2: Objective Response Rate (ORR)Time frame: Up to 37 months
  3. Combination 2: Composite Response Rate (RR)Time frame: Up to 31 months
  4. Combination 1: Part 2: Number of Participants With Adverse Events (AEs)Time frame: Up to 37 months
  5. Combination 2: Number of Participants With Adverse Events (AEs)Time frame: Up to 31 months
  6. Combination 1: Part 2: Number of Participants With Adverse Events (AEs) of Grade >=3 SeverityTime frame: Up to 37 months
  7. Combination 2: Number of Participants With Adverse Events (AEs) of Grade >=3 SeverityTime frame: Up to 31 months
  8. Combination 3: Maximum Observed Plasma Concentration (Cmax) of Niraparib and Abiraterone Acetate After a Single DoseTime frame: Pre-dose, 30 min, 1 hour (hr), 1.5 hr, 2hr, 3 hr, 4 hr, 6 hr, 8 hr, 10 hr, 24 hr, 48 hr, 72 hr, and 168 hr post dose on Day 1
  9. Combination 3: Maximum Observed Plasma Concentration (Cmax) of Niraparib Normalized by the Dose(Niraparib) (Cmax/Dose) of Niraparib Administered With AA After a Single DoseTime frame: Pre-dose, 30 min, 1 hour (hr), 1.5 hr, 2hr, 3 hr, 4 hr, 6 hr, 8 hr, 10 hr, 24 hr, 48 hr, 72 hr, and 168 hr post dose on Day 1
  10. Combination 3: Area Under the Plasma Concentration-Time Curve From Time Zero to 168 Hours (AUC [0-168hr]) of Niraparib Administered With AA After a Single DoseTime frame: Pre-dose, 30 min, 1 hour (hr), 1.5 hr, 2hr, 3 hr, 4 hr, 6 hr, 8 hr, 10 hr, 24 hr, 48 hr, 72 hr, and 168 hr post dose on Day 1
  11. Combination 3: Area Under the Plasma Concentration-Time Curve for Niraparib From Time Zero to 168 Hours (AUC [0-168 Hours]/Dose) of Niraparib Administered With AA After a Single DoseTime frame: Pre-dose, 30 min, 1 hour (hr), 1.5 hr, 2hr, 3 hr, 4 hr, 6 hr, 8 hr, 10 hr, 24 hr, 48 hr, 72 hr, and 168 hr post dose on Day 1

Locations

50 sites in 7 countries. Site status is shown where the registry gives one.

  • Urological Associates of Southern Arizona, P.C.

    Tucson, Arizona

  • The Urology Center of Colorado

    Denver, Colorado

  • Mayo Clinic - Division Of Hematology/oncology

    Jacksonville, Florida

  • First Urology, PSC

    Jeffersonville, Indiana

  • Chesapeake Urology Research Associates

    Towson, Maryland

  • Michigan Institute of Urology

    Troy, Michigan

  • New York Oncology Hematology

    Albany, New York

  • Memorial Sloan Kettering Cancer Center 1

    Harrison, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center (UPMC)

    Pittsburgh, Pennsylvania

  • MUSC-Hollings Cancer Center

    Charleston, South Carolina

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina

  • Urology Associates

    Nashville, Tennessee

  • Houston Metro Urology

    Houston, Texas

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Utah Cancer Specialists

    Salt Lake City, Utah

  • Urology of Virginia, PLCC

    Virginia Beach, Virginia

  • University of Wisconsin Carbone Cancer Center

    Madison, Wisconsin

  • OLV Ziekenhuis Aalst

    Aalst, Belgium

  • ZNA Middelheim

    Antwerp, Belgium

  • ULB Hôpital Erasme

    Brussels, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • Az Groeninge

    Kortrijk, Belgium

  • Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman

    Liège, Belgium

  • Southern Alberta Institute of Urology / Prostate Cancer Centre

    Calgary, Alberta, Canada

  • British Columbia Cancer Agency

    Vancouver, British Columbia, Canada

  • Princess Margaret Cancer Centre University Health Network

    Toronto, Ontario, Canada

  • Centre de Recherche du CHUM

    Montreal, Quebec, Canada

  • Asaf Harofe Medical Center

    Beer Yaakov, Israel

  • Soroka Hospital

    Beersheba, Israel

  • Rambam Medical Center

    Haifa, Israel

  • Rabin Medical Center

    Petah Tikva, Israel

  • Sheba Medical Center Tel Hashomer

    Ramat Gan, Israel

  • Azienda Ospedaliera Universitaria Careggi di Firenze

    Florence, Italy

  • Azienda Ospedaliera ''Vito Fazzi''

    Lecce, Italy

  • ASST Grande Ospedale Metropolitano Niguarda

    Milan, Italy

  • IRCCS-Fondazione Pascale

    Naples, Italy

  • UOC Oncologia Ospedale Provinciale di Macerata

    Province of Macerata, Italy

  • Hosp. de La Santa Creu I Sant Pau

    Barcelona, Spain

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.